EFFICACY OF PROTON PUMP INHIBITORS-BASED REGIMENS FOR THE THERAPY OF HELICOBACTERIA PYLORI INFECTION: CURRENT STATUS IN THE MIDDLE EAST REGION: A REVIEW

Omar Alshargi; Samah Alzaid; Zainab Albahouth; Mawaddah Ageeli; Maram Asiri; Amer Asiri

doi:10.46903/gjms/21.04.1475

EFFICACY OF PROTON PUMP INHIBITORS-BASED REGIMENS FOR THE THERAPY OF HELICOBACTERIA PYLORI INFECTION: CURRENT STATUS IN THE MIDDLE EAST REGION: A REVIEW

Omar Alshargi, Samah Alzaid, Zainab Albahouth, Mawaddah Ageeli, Maram Asiri, Amer Asiri

Abstract

Helicobacter pylori (H. pylori) infection affects millions of people worldwide, including Middle East. There are several treatment regimens available to treat the illness caused by this organism. In order to eradicate the H. pylori infection in the Middle East, proton pump inhibitor (PPI)-based regimens are increasingly being reported in the literature, which was the focus of this study. We studied the regimens used in various nations to identify the most effective and widely used (PPI)-based regimen in clinical settings. Although a PPI and two antibiotics for 10- to 14-day course of treatment have traditionally been used to treat such infections, there are now several alternatives. Quadruple therapies like bismuth have demonstrated improved H. pylori eradication. Thus, they are suggested as primary treatments in Middle Eastern regions where resistance rates are lower. Quadruple therapy that includes bismuth has shown superior H. pylori eradication over traditional triple regimens. As a result, it has been recommended as first-line treatment in Middle Eastern countries where resistance is less common.

Keywords

Efficacy; Helicobacter pylori; Middle East; Proton Pump Inhibitors; Peptic Ulcer Disease.

Full Text:

PDF

References

Prabhu R, Sathali AAH. A Perspective Review of Helicobacter Pylori.Frontiers in Life Science. Bhurni Pub. 2021(I):119-126.

Al-Badriyeh D, Alabbadi I, Fahey M, Al-Khal A, Zaidan M. Multi-indication pharmacotherapeutic multicriteria decision analytic model for the comparative formulary inclusion of proton pump inhibitors in Qatar. Clinical therapeutics. 2016;38(5):1158-73. https://doi.org/10.1016/j.clinthera.2016.03.004

Forgacs I, Loganayagam A. Overprescribing proton pump inhibitors. British Medical Journal Publishing Group; 2008:p.2-3. https://doi.org/10.1136/bmj.39406.449456.BE

Ksiądzyna D, Szeląg A, Paradowski L. Overuse of proton pump inhibitors. Pol Arch Med Wewn. 2015;125(4):289-98. https://doi.org/10.20452/pamw.2790

Hindy J-R, Souaid T, Larus CT, Glanville J, Aboujaoude R. Nexplanon migration into a subsegmental branch of the pulmonary artery: a case report and review of the literature. Medicine. 2020;99(4). https://doi.org/10.1097/MD.0000000000018881

Sablet T, Piazuelo MB, Shaffer CL, Schneider BG, Asim M, Chaturvedi R, et al. Phylogeographic origin of Helicobacter pylori is a determinant of gastric cancer risk. Gut. 2011;60(9):1189-95. https://doi.org/10.1136/gut.2010.234468

Ghotaslou R, Leylabadlo HE, Asl YM. Prevalence of antibiotic resistance in Helicobacter pylori: A recent literature review. World journal of methodology. 2015;5(3):164. https://doi.org/10.5662/wjm.v5.i3.164

Hooi JK, Lai WY, Ng WK, Suen MM, Underwood FE, Tanyingoh D, et al. Global prevalence of Helicobacter pylori infection: systematic review and meta-analysis. Gastroenterology. 2017;153(2):420-9. https://doi.org/10.1053/j.gastro.2017.04.022

Nakayama SF, Yoshikane M, Onoda Y, Nishihama Y, Iwai-Shimada M, Takagi M, et al. Worldwide trends in tracing poly-and perfluoroalkyl substances (PFAS) in the environment. TrAC Trends in Analytical Chemistry. 2019;121:115410. https://doi.org/10.1016/j.trac.2019.02.011

Zhang L, Jang H, Liu H, Kim MG, Yang D, Liu S, et al. Sodium-Decorated Amorphous/Crystalline RuO2 with Rich Oxygen Vacancies: A Robust pH-Universal Oxygen Evolution Electrocatalyst. Angewandte Chemie International Edition. 2021;60(34):18821-9. https://doi.org/10.1002/anie.202106631

Yousefi B, Mohammadlou M, Abdollahi M, Salek Farrokhi A, Karbalaei M, Keikha M, et al. Epigenetic changes in gastric cancer induction by Helicobacter pylori. Journal of cellular physiology. 2019;234(12):21770-84. https://doi.org/10.1002/jcp.28925

Butt J, Varga MG, Wang T, Tsugane S, Shimazu T, Zheng W, et al. Smoking, Helicobacter pylori serology, and gastric cancer risk in prospective studies from China, Japan, and Korea. Cancer Prevention Research. 2019;12(10):667-74. https://doi.org/10.1158/1940-6207.CAPR-19-0238

Lu X, Zhang L, Wang X, Gao M, Li K, Zhang Y, et al. Rapid increases in warm-season surface ozone and resulting health impact in China since 2013. Environmental Science & Technology Letters. 2020;7(4):240-7. https://doi.org/10.1021/acs.estlett.0c00171

Liang C-M, Tai W-C, Hsu P-I, Wu D-C, Kuo C-H, Tsay F-W, et al. Trend of changes in antibiotic resistance in Helicobacter pylori from 2013 to 2019: a multicentre report from Taiwan. Therapeutic advances in gastroenterology. 2020;13:1756284820976990. https://doi.org/10.1177/1756284820976990

Zhang J, Rong C, Yan C, Chen J, Yang W, Yu L, et al. Risk factors of furazolidone-associated fever. PloS one. 2022;17(4):e0266763. https://doi.org/10.1371/journal.pone.0266763

Mansori K, Moradi Y, Naderpour S, Rashti R, Moghaddam AB, Saed L, et al. Helicobacter pylori infection as a risk factor for diabetes: a meta-analysis of case-control studies. BMC gastroenterology. 2020;20(1):1-14. https://doi.org/10.1186/s12876-020-01223-0

Kulhánová I, Znaor A, Shield KD, Arnold M, Vignat J, Charafeddine M, et al. Proportion of cancers attributable to major lifestyle and environmental risk factors in the Eastern Mediterranean region. International journal of cancer. 2020;146(3):646-56. https://doi.org/10.1002/ijc.32284

Yuan C, Adeloye D, Luk TT, Huang L, He Y, Xu Y, et al. The global prevalence of and factors associated with Helicobacter pylori infection in children: a systematic review and meta-analysis. The Lancet Child & Adolescent Health. 2022;6(3):185-194. https://doi.org/10.1016/S2352-4642(21)00400-4

Sirkeci Ö, Sirkeci EE, Ulaş T. The Prevalence of Helicobacter pylori in Northern Cyprus: A Retrospective Study. 2022;7(3):346-348. https://doi.org/10.4274/cjms.2021.3565

Vishnu P, Duncan J, Connell N, Cooper N, Lim W, Rodeghiero F, et al. International survey on Helicobacter pylori testing in patients with immune thrombocytopenia: Communication of the platelet immunology scientific and standardization committee. Journal of Thrombosis and Haemostasis. 2021;19(1):287-96. https://doi.org/10.1111/jth.15136

Khoder G, Mina S, Mahmoud I, Muhammad JS, Harati R, Burucoa C. Helicobacter pylori Infection in Tripoli, North Lebanon: assessment and risk factors. Biology. 2021;10(7):599. https://doi.org/10.3390/biology10070599

Yasser Arafath A. Prospective study on Association of H. pylori Infection in Gastro Duodenal Perforation Peritonitis: Madurai Medical College, Madurai; 2020.

Poitras P, Bradette M, Groleau V, Ratelle R, Marchand X, Armstrong D. The Stomach. The Digestive System: From Basic Sciences to Clinical Practice: Springer; 2022; 31-65. https://doi.org/10.1007/978-3-030-98381-9_2

Bardou M, Fortinsky KJ, Chapelle N, Luu M, Barkun A. An update on the latest chemical therapies for reflux esophagitis in children. Expert Opinion on Pharmacotherapy. 2019;20(2):231-9. https://doi.org/10.1080/14656566.2018.1549224

Guo CG, Zhang F, Wu JT, Cheung KS, Li B, Law SY, et al. Divergent trends of hospitalizations for upper and lower gastrointestinal bleeding based on population prescriptions of aspirin, proton pump inhibitors and Helicobacter pylori eradication therapy: Trends of upper and lower gastrointestinal bleeding. UEG Journal. 2021;9(5):543-51. https://doi.org/10.1002/ueg2.12067

Abdollahi H, Hashemzadeh M, Khoshnood S, Savari M. Characterization of helicobacter pylori genotypes from Iranian patients with gastric clinical diseases: predominance of vacA s1a and cagA EPIYA-ABC genotypes. Gene Reports. 2019;16:100458. https://doi.org/10.1016/j.genrep.2019.100458

Pichon M, Luzarraga V, Burucoa C. Mutations Associated to Antibiotic-Resistant Helicobacter pylori: It Is Time to Validate Sequencing Observations. J Clin Med 2022;11(15)-4293. https://doi.org/10.3390/jcm11154293

Mancini NL, Rajeev S, Jayme TS, Wang A, Keita ÅV, Workentine ML, et al. Crohn's disease pathobiont adherent-invasive E coli disrupts epithelial mitochondrial networks with implications for gut permeability. Cellular and molecular gastroenterology and hepatology. 2021;11(2):551-71. https://doi.org/10.1016/j.jcmgh.2020.09.013

Kamada T, Satoh K, Itoh T, Ito M, Iwamoto J, Okimoto T, et al. Evidence-based clinical practice guidelines for peptic ulcer disease 2020. Journal of gastroenterology. 2021;56(4):303-22. https://doi.org/10.1007/s00535-021-01769-0

Watanabe T, Fujiwara Y, Chan FK. Current knowledge on non-steroidal anti-inflammatory drug-induced small-bowel damage: a comprehensive review. Journal of gastroenterology. 2020;55(5):481-95. https://doi.org/10.1007/s00535-019-01657-8

Joo MK, Park CH, Kim JS, Park JM, Ahn JY, Lee BE, et al. Clinical Guidelines for Drug-Related Peptic Ulcer. Gut and Liver. 2020;14(6):707. https://doi.org/10.5009/gnl20246

Hoteit M, Mattar E, Racil Allaw AAR. Epidemiological Study Assessing the Overuse of Proton Pump Inhibitors in Lebanese Population. Middle East Journal of Digestive Diseases. 2020;12(4):265.

Aishwarya S, Gunasekaran K. Meta-analysis of the microbial biomarkers in the gut-lung crosstalk in COVID-19, community-acquired pneumonia and Clostridium difficile infections. Letters in Applied Microbiology. 2022;75(5):1293-306. https://doi.org/10.1111/lam.13798

Patel P, Deshpande A, Yu P-C, Imrey PB, Lindenauer PK, Zilberberg MD, et al. Association of fluoroquinolones or cephalosporin plus macrolide with Clostridioides difficile infection (CDI) after treatment for community-acquired pneumonia. Infection Control & Hospital Epidemiology. 2022:1-8. https://doi.org/10.1017/ice.2022.60

Lee J-C, Hung Y-P, Tsai B-Y, Tsai P-J, Ko W-C. Severe Clostridium difficile infections in intensive care units: Diverse clinical presentations. Journal of Microbiology, Immunology and Infection. 2021;54(6):1111-7. https://doi.org/10.1016/j.jmii.2020.07.012

Perumal R, van Zyl-Smit R. Community-acquired pneumonia: The need to broaden our diagnostic armamentarium. African Journal of Thoracic and Critical Care Medicine. 2020;26(1):2-3. https://doi.org/10.7196/AJTCCM.2020.v26i1.063

Pichon M, Freche B, Burucoa C. New Strategy for the Detection and Treatment of Helicobacter pylori Infections in Primary Care Guided by a Non-Invasive PCR in Stool: Protocol of the French HepyPrim Study. Journal of Clinical Medicine. 2022;11(5):1151. https://doi.org/10.3390/jcm11051151

Houso A, Hamdan M, Falana H. Cost benefit analysis of clinical pharmacist interventions in medical intensive care unit in Palestine medical complex: Prospective interventional study. Saudi Pharmaceutical Journal. 2022;30(12):1718-24. https://doi.org/10.1016/j.jsps.2022.09.017

Shah SC, Iyer PG, Moss SF. AGA clinical practice update on the management of refractory Helicobacter pylori infection: expert review. Gastroenterology. 2021;160(5):1831-41. https://doi.org/10.1053/j.gastro.2020.11.059

Gisbert JP. Empirical or susceptibility-guided treatment for Helicobacter pylori infection? A comprehensive review. Therapeutic Advances in Gastroenterology. 2020;13:1756284820968736. https://doi.org/10.1177/1756284820968736

O'Connor A, Furuta T, Gisbert JP, O'Morain C. Review-treatment of Helicobacter pylori infection 2020. Helicobacter. 2020;25:e12743. https://doi.org/10.1111/hel.12743

Egan B, Katicic M, O'connor H, O'Morain C. Treatment of Helicobacter pylori. Helicobacter. 2007;12:31-7. https://doi.org/10.1111/j.1523-5378.2007.00538.x

Vakil N, Vaira D. Treatment for H. pylori infection: new challenges with antimicrobial resistance. Journal of clinical gastroenterology. 2013;47(5):383-8. https://doi.org/10.1097/MCG.0b013e318277577b

Bock C, Lengauer T. Managing drug resistance in cancer: lessons from HIV therapy. Nature Reviews Cancer. 2012;12(7):494-501. https://doi.org/10.1038/nrc3297

Sun Q, Liang X, Zheng Q, Liu W, Xiao S, Gu W, et al. High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication. Helicobacter. 2010;15(3):233-8. https://doi.org/10.1111/j.1523-5378.2010.00758.x

Uygun A, Kadayifci A, Safali M, Ilgan S, Bagci S. The efficacy of bismuth containing quadruple therapy as a first-line treatment option for Helicobacter pylori. Journal of digestive diseases. 2007;8(4):211-5. https://doi.org/10.1111/j.1751-2980.2007.00308.x

Fallone CA, Moss SF, Malfertheiner P. Reconciliation of recent Helicobacter pylori treatment guidelines in a time of increasing resistance to antibiotics. Gastroenterology. 2019;157(1):44-53. https://doi.org/10.1053/j.gastro.2019.04.011

Zhang W, Chen Q, Liang X, Liu W, Xiao S, Graham DY, et al. Bismuth, lansoprazole, amoxicillin and metronidazole or clarithromycin as first-line Helicobacter pylori therapy. Gut. 2015;64(11):1715-20. https://doi.org/10.1136/gutjnl-2015-309900

Von Dollen KA, Jones M, Beachler T, Harris TL, Papich MG, Lyle SK, et al. Antimicrobial activity of ceftiofur and penicillin with gentamicin against Escherichia coli and Streptococcus equi subspecies zooepidemicus in an ex vivo model of equine postpartum uterine disease. Journal of equine veterinary science. 2019;79:121-6. https://doi.org/10.1016/j.jevs.2019.06.005

Gisbert J, Calvet X. The effectiveness of standard triple therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough. Alimentary pharmacology & therapeutics. 2011;34(11-12):1255-68. https://doi.org/10.1111/j.1365-2036.2011.04887.x

Wermeille J, Cunningham M, Dederding J-P, Girard L, Baumann R, Zelger G, et al. Failure of Helicobacter pylori eradication: is poor compliance the main cause? Gastroenterologie clinique et biologique. 2002;26(3):216-9.

Essa AS, Kramer JR, Graham DY, Treiber G. Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing "concomitant therapy" versus triple therapy for Helicobacter pylori eradication. Helicobacter. 2009;14(2):109-18. https://doi.org/10.1111/j.1523-5378.2009.00671.x

Malfertheiner P. Bismuth improves PPI-based triple therapy for H. pylori eradication. Nature Reviews Gastroenterology & Hepatology. 2010;7(10):538-9. https://doi.org/10.1038/nrgastro.2010.131

Malfertheiner P, Bazzoli F, Delchier J-C, Celiñski K, Giguère M, Rivière M, et al. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. The Lancet. 2011;377(9769):905-13. https://doi.org/10.1016/S0140-6736(11)60020-2

Van der Hulst R, Van der Ende A, Homan A, Roorda P, Dankert J, Tytgat G. Influence of metronidazole resistance on efficacy of quadruple therapy for Helicobacter pylori eradication. Gut. 1998;42(2):166-9. https://doi.org/10.1136/gut.42.2.166

Dehghani SM, Erjaee A, Imanieh MH, Haghighat M. Efficacy of the standard quadruple therapy versus triple therapies containing proton pump inhibitor plus amoxicillin and clarithromycin or amoxicillin-clavulanic acid and metronidazole for Helicobacter pylori eradication in children. Digestive diseases and sciences. 2009;54(8):1720-4. https://doi.org/10.1007/s10620-008-0547-9

Bahremand S, Nematollahi LR, Fourutan H, Tirgari F, Nouripour S, Mir E, et al. Evaluation of triple and quadruple Helicobacter pylori eradication therapies in Iranian children: a randomized clinical trial. European journal of gastroenterology & hepatology. 2006;18(5):511-4. https://doi.org/10.1097/00042737-200605000-00009

Jones NL, Koletzko S, Goodman K, Bontems P, Cadranel S, Casswall T, et al. Joint ESPGHAN/NASPGHAN guidelines for the management of Helicobacter pylori in children and adolescents (update 2016). Journal of pediatric gastroenterology and nutrition. 2017;64(6):991-1003. https://doi.org/10.1097/MPG.0000000000001594

Kato S, Konno M, Maisawa S-i, Tajiri H, Yoshimura N, Shimizu T, et al. Results of triple eradication therapy in Japanese children: a retrospective multicenter study. Journal of gastroenterology. 2004;39(9):838-43. https://doi.org/10.1007/s00535-004-1398-6

Jun J-S, Seo J-H, Park J-S, Rhee K-H, Youn H-S. Changes in the treatment strategies for Helicobacter pylori infection in children and adolescents in Korea. Pediatric Gastroenterology, Hepatology & Nutrition. 2019;22(5):417-30. https://doi.org/10.5223/pghn.2019.22.5.417

O'Connor A, Lamarque D, Gisbert JP, O'Morain C. Treatment of Helicobacter pylori infection 2017. Helicobacter. 2017;22:e12410. https://doi.org/10.1111/hel.12410

Alhalabi M, Alassi MW, Alaa Eddin K, Cheha K. Efficacy of two-week therapy with doxycycline-based quadruple regimen versus levofloxacin concomitant regimen for helicobacter pylori infection: a prospective single-center randomized controlled trial. BMC Infectious Diseases. 2021;21(1):1-6. https://doi.org/10.1186/s12879-021-06356-5

Minakari M, Davarpanah Jazi AH, Shavakhi A, Moghareabed N, Fatahi F. A randomized controlled trial: efficacy and safety of azithromycin, ofloxacin, bismuth, and omeprazole compared with amoxicillin, clarithromycin, bismuth, and omeprazole as second-line therapy in patients with Helicobacter pylori infection. Helicobacter. 2010;15(2):154-9. https://doi.org/10.1111/j.1523-5378.2009.00739.x

McNicholl AG, Marin AC, Molina-Infante J, Castro M, Barrio J, Ducons J, et al. Randomised clinical trial comparing sequential and concomitant therapies for Helicobacter pylori eradication in routine clinical practice. Gut. 2014;63(2):244-9. https://doi.org/10.1136/gutjnl-2013-304820

Gungor G, Baglıcakoglu M, Kayacetin E, Biyik M, Ucar R, Goktepe H, et al. Current status of five different regimens for empiric first-line Helicobacter pylori eradication in Turkey. Digestion. 2015;92(2):55-9. https://doi.org/10.1159/000434627

Kim SY, Lee SW, Choe JW, Jung SW, Hyun JJ, Jung YK, et al. Helicobacter pylori eradication rates of concomitant and sequential therapies in Korea. Helicobacter. 2017;22(6):e12441. https://doi.org/10.1111/hel.12441

Gisbert J, Calvet X. Non-bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori. Alimentary pharmacology & therapeutics. 2011;34(6):604-17. https://doi.org/10.1111/j.1365-2036.2011.04770.x

Gisbert JP, Calvet X. Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori. Clinical and experimental gastroenterology. 2012:23-34. https://doi.org/10.2147/CEG.S25419

Chey WD, Wong BC, Gastroenterology PPCotACo. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Official journal of the American College of Gastroenterology| ACG. 2007;102(8):1808-25. https://doi.org/10.1111/j.1572-0241.2007.01393.x

Guadagnoli L, Simons M, McGarva J, Taft TH, van Tilburg MA. Improving Patient Adherence to Lifestyle Changes for the Management of Gastroesophageal Reflux. Patient preference and adherence. 2022;16:897. https://doi.org/10.2147/PPA.S356466

Zahreddine L, Hallit S, Shakaroun S, Al-Hajje A, Awada S, Lahoud N. Knowledge of pharmacists and parents towards antibiotic use in pediatrics: a cross-sectional study in Lebanon. Pharmacy Practice (Granada). 2018;16(3). https://doi.org/10.18549/PharmPract.2018.03.1194

Hallit S, Zahreddine L, Saleh N, Shakaroun S, Lahoud N. Practice of parents and pharmacists regarding antibiotics use in pediatrics: A 2017 cross-sectional study in Lebanese community pharmacies. Journal of Evaluation in Clinical Practice. 2020;26(1):181-9. https://doi.org/10.1111/jep.13165

Sawaya RD, Wakil C, Wazir A, Shayya S, Berbari I, Safa R, et al. Does implementation of the PECARN rules for minor head trauma improve patient-centered outcomes in a lower resource emergency department: a retrospective cohort study. BMC pediatrics. 2020;20(1):1-11. https://doi.org/10.1186/s12887-020-02328-x

Jones DW, Appel LJ, Sheps SG, Roccella EJ, Lenfant C. Measuring blood pressure accurately: new and persistent challenges. Jama. 2003;289(8):1027-30. https://doi.org/10.1001/jama.289.8.1027

Piper AM, Batovska J, Cogan NO, Weiss J, Cunningham JP, Rodoni BC, et al. Prospects and challenges of implementing DNA metabarcoding for high-throughput insect surveillance. GigaScience. 2019;8(8):giz092. https://doi.org/10.1093/gigascience/giz092

McGrath JM. Physicians' perspectives on communicating prescription drug information. Qualitative Health Research. 1999;9(6):731-45. https://doi.org/10.1177/104973299129122243

Jimmy B, Jose J. Patient medication adherence: measures in daily practice. Oman medical journal. 2011;26(3):155. https://doi.org/10.5001/omj.2011.38

Makoul G, Arntson P, Schofield T. Health promotion in primary care: physician-patient communication and decision making about prescription medications. Social science & medicine. 1995;41(9):1241-54. https://doi.org/10.1016/0277-9536(95)00061-B

Soubra L, Issa M. Prescribing of proton pump inhibitors for gastrointestinal bleeding prophylaxis in the Lebanese outpatient setting: patterns, compliance with guidelines and risks. International Journal of Pharmacy Practice. 2019;27(4):386-92. https://doi.org/10.1111/ijpp.12537

Almeida N, Romaozinho JM, Donato MM, Luxo C, Cardoso O, Cipriano MA, et al. Triple Therapy with High-Dose Proton-Pump Inhibitor, Amoxicillin, and Doxycycline Is Useless for H elicobacter pylori Eradication: A Proof-of-Concept Study. Helicobacter. 2014;19(2):90-7. https://doi.org/10.1111/hel.12106

Alihosseini S, Ghotaslou R, Heravi FS, Ahmadian Z, Leylabadlo HE. Management of antibiotic-resistant Helicobacter pylori infection: current perspective in Iran. Journal of Chemotherapy. 2020;32(6):273-85. https://doi.org/10.1080/1120009X.2020.1790889

Maleki Kakelar H, Barzegari A, Dehghani J, Hanifian S, Saeedi N, Barar J, et al. Pathogenicity of Helicobacter pylori in cancer development and impacts of vaccination. Gastric Cancer. 2019;22(1):23-36. https://doi.org/10.1007/s10120-018-0867-1

Arj A, Mollaei M, Razavizadeh M, Moraveji A. The comparison of levofloxacin-and clarithromycin-based bismuth quadruple therapy regimens in Helicobacter pylori eradication. Journal of Research in Pharmacy Practice. 2020;9(2):101. https://doi.org/10.4103/jrpp.JRPP_19_86

Fawzy HR, Abdelmageed AM, Shoulkamy MA, Abdel Wahab M, Ismail H. Non-invasive follow-up of Egyptian patients infected with Helicobacter pylori by quantification of H. pylori circulating antigen in serum using ELISA. Journal of Bioscience and Applied Research. 2022:247-63. https://doi.org/10.21608/jbaar.2022.267000

Kesli R, Bilgin H, Unlu Y, Gungor G. Evaluation of Diagnostic Performance of Culture, Rapid Urease Test and Histopathology in the Diagnosis of Helicobacter pylori Infection, and In Vitro Activity of Various Antimicrobials Against Helicobacter pylori/Helicobacter pylori Infeksiyonu Tanisinda Kultur, Hizli Ureaz Testi ve Histopatolojinin Tani Degerlerinin ve Cesitli Antimikrobiyallerin Helicobacterpylori'ye Karsi In Vitro Etkilerinin Incelenmesi. KLIMIK Journal. 2022;35(1):36-40. https://doi.org/10.36519/kd.2022.3573

Hadi HI, Enaya MA, Enaya M, Aljanaby A. Duodenal ulcer and gastric cancer patients infected with Helicobacter Pylori in AL-Najaf City, Iraq. International Journal of Health Sciences. 2022;6:8789-93. https://doi.org/10.53730/ijhs.v6nS5.11790

Safiri S, Sepanlou SG, Ikuta KS, Bisignano C, Salimzadeh H, Delavari A, et al. The global, regional, and national burden of colorectal cancer and its attributable risk factors in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. The lancet Gastroenterology & hepatology. 2019;4(12):913-33. https://doi.org/10.1016/S2468-1253(19)30345-0

Alsohaibani F, Peedikayil M, Alshahrani A, Somily A, Alsulaiman R, Azzam N, et al. Practice guidelines for the management of Helicobacter pylori infection: The Saudi H. pylori Working Group recommendations. Saudi J of Gastroenterol: 2023;29(6):326-246. https://doi.org/10.4103/sjg.sjg_288_22

Zamani A, Shariat M, OLOOMI YZ, Bahremand S, AKBARI AP, Dejakam A. Relationship between Helicobacter pylori infection and serum ferritin level in primary school children in Tehran-Iran. Acta Med Iran2011;49(5):314-8.

Assem M, El Azab G, Rasheed MA, Abdelfatah M, Shastery M. Efficacy and safety of Levofloxacin, Clarithromycin and Esomeprazol as first line triple therapy for Helicobacter pylori eradication in Middle East. Prospective, randomized, blind, comparative, multicenter study. European Journal of Internal Medicine. 2010;21(4):310-4. https://doi.org/10.1016/j.ejim.2010.05.011

O'Connor A, Gisbert JP, McNamara D, O'Morain C. Treatment of Helicobacter pylori infection 2010. Helicobacter. 2010;15:46-52. https://doi.org/10.1111/j.1523-5378.2010.00774.x

Smith SI, Ajayi A, Jolaiya T, Onyekwere C, Setshedi M, Schulz C, et al. Helicobacter pylori infection in Africa: update of the current situation and challenges. Digestive Diseases. 2022;40(4):535-44. https://doi.org/10.1159/000518959

O'Connor A, Gisbert JP, O'Morain C, Ladas S. Treatment of Helicobacter pylori infection 2015. Helicobacter. 2015;20:54-61. https://doi.org/10.1111/hel.12258

Mansour-Ghanaei F, Joukar F, Mojtahedi K, Sokhanvar H, Askari K, Shafaeizadeh A. Does treatment of Helicobacter pylori infection reduce gastric precancerous lesions? Asian Pacific Journal of Cancer Prevention. 2015;16(4):1571-4. https://doi.org/10.7314/APJCP.2015.16.4.1571

Boltin D, Kimchi N, Dickman R, Gingold-Belfer R, Niv Y, Birkenfeld S. Attitudes and practice related to Helicobacter pylori infection among primary care physicians. European journal of gastroenterology & hepatology. 2016;28(9):1035-40. https://doi.org/10.1097/MEG.0000000000000659

Mohammadi M, Attaran B, Malekzadeh R, Graham DY. Furazolidone, an underutilized drug for H. pylori eradication: lessons from Iran. Digestive diseases and sciences. 2017;62(8):1890-6. https://doi.org/10.1007/s10620-017-4628-5

Pellicano R, Ribaldone DG, Caviglia GP. Strategies for Helicobacter pylori eradication in the year 2020. Saudi J Gastrol 2020;26(2):63-65.. https://doi.org/10.4103/sjg.SJG_95_20

DOI: https://doi.org/10.46903/gjms/21.04.1475